• In the CRUISE trial, vascular complications were defined as hematoma, re-bleed after hemostasis, and pseudoaneurysm. These occurred in 9.3% and 9.8% of enoxaparin and UFH groups, respectively (P = 1.0). There were no occurrences of atrioventricular fistula in either group.

• Angiographic complications were defined as major dissection, abrupt closure, thrombus formation, no reflow, and side-branch closure. These occurred in 6.3% and 6.2% of enoxaparin and UFH groups, respectively (P = 1.0).

• MI occurred within 48 h in 8.5% and 7.6% of enoxaparin and UFH patients, respectively (P = 0.82).¹

• The CRUISE investigators concluded that compared with UFH plus eptifibatide, enoxaparin plus the same GP Iib/IIIa inhibitor is not associated with excess of bleeding or vascular, angiographic, or clinical complications.

¹ Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention. Results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin study. J Am Coll Cardiol. 2003;41:20-25.